Treating Multiple Myeloma with Arsenic

Multiple myeloma is a unique cancer of plasma cells that attacks and destroys bone. Due to its complexity, the disease can be difficult to diagnose and often results in varying treatment recommendations from doctors.

Scientists have recently found that arsenic (As), a poisonous metalloid used in pesticides, herbicides and insecticides can be used in treating multiple myeloma. This abc7 news clip reports on how arsenic is used to treat multiple myeloma.

New therapies are changing the outlook for blood cancer patients

Medical News Today: The International Myeloma Foundation (IMF) - conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate the breadth of the gains being made in the treatment of multiple myeloma and related blood cancers.

The findings show that new treatment regimens that began with THALOMID® and extend to both VELCADE® and the newest oral treatment REVLIMID® are helping a growing range of myeloma patients when used alone, sequentially and in various combinations. Collectively, these studies represent a significant increase in knowledge of how myeloma responds to treatment, which is already becoming applicable to other cancers.

The patient groups studied cover the full range, from relapsed patients to the newly diagnosed, young to old, and include patients with an otherwise poor prognosis due to chromosomal abnormalities. In some cases the data being presented at the conference significantly advances previous studies to show long-term response in newly diagnosed patients. In one of the most significant studies, researchers from the Mayo Clinic report 67% of patients using REVLIMID (plus the steroid dexamethasone) as primary therapy, achieved a response categorized as complete or very good, with a low rate of disease progression continuing even after two years.

Read more this story…